Loading...
•
Sep 30, 2024
Phibro Q1 2025 Earnings Report
Reported strong first quarter results with significant growth in net sales and adjusted EBITDA.
Key Takeaways
Phibro Animal Health Corporation reported a strong first quarter with net sales increasing by 13% to $260.4 million and net income of $7.0 million. Adjusted EBITDA increased by 64% to $30.7 million, driven by strong performance in the Vaccines business and recovery in Mineral Nutrition and Performance Products. The company updated its fiscal year 2025 guidance, projecting net sales of $1.05 billion to $1.10 billion and adjusted EBITDA of $124 million to $132 million.
Net sales increased by 13% to $260.4 million.
Net income increased to $7.0 million, a $15.0 million increase.
Adjusted EBITDA increased by 64% to $30.7 million.
Updated fiscal year 2025 guidance projects net sales of $1.05 billion to $1.10 billion and adjusted EBITDA of $124 million to $132 million.
Phibro
Phibro
Phibro Revenue by Segment
Revenue by Segment
Animal Health Revenue
CapyFin.comMFAs and Other Revenue
CapyFin.comNutritional Specialties Revenue
CapyFin.comVaccines Revenue
CapyFin.comMineral Nutrition Revenue
CapyFin.comPerformance Products Revenue
CapyFin.com Forward Guidance
Phibro has updated its fiscal year 2025 guidance, which includes net sales of $1.05 billion to $1.10 billion and adjusted EBITDA of $124 million to $132 million. This guidance is on a standalone basis without giving effect to the acquisition of Zoetis’ Medicated Feed Additive portfolio.
Revenue & Expenses
Visualization of income flow from segment revenue to net income